Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

PROCEPT BioRobotics (PRCT) EPS (Weighted Average and Diluted) (2020 - 2026)

PROCEPT BioRobotics has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.56 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 24.44% to -$0.56 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.82 through Mar 2026, down 7.69% year-over-year, with the annual reading at -$1.72 for FY2025, 1.71% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.56 for Q1 2026 at PROCEPT BioRobotics, down from -$0.53 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.34 in Q4 2024 and troughed at -$0.63 in Q1 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.51 (2022), against an average of -$0.48.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 85.28% in 2022 against a maximum downside of 131.34% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.63 in 2022, then increased by 14.29% to -$0.54 in 2023, then surged by 37.04% to -$0.34 in 2024, then tumbled by 55.88% to -$0.53 in 2025, then fell by 5.66% to -$0.56 in 2026.
  • Per Business Quant, the three most recent readings for PRCT's EPS (Weighted Average and Diluted) are -$0.56 (Q1 2026), -$0.53 (Q4 2025), and -$0.38 (Q3 2025).